All In Biotech

Drug Trial Radar · NCT00077311

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Aug 2004

Primary completion

Jul 2006

Study completion Apr 2009

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Feb 12, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dimesna, may help prevent or decrease the side effects (such as nerve, kidney, and inner ear damage) caused by chemotherapy. PURPOSE: This randomized phase II trial is studying giving docetaxel and cisplatin together with dimesna to see how well it works compared to giving docetaxel and cisplatin alone in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Conditions

  • Anemia
  • Drug/Agent Toxicity by Tissue/Organ
  • Lung Cancer
  • Neutropenia

Interventions

  • darbepoetin alfaBiological

    200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL

  • pegfilgrastimBiological

    6 mg sub Q day 2 of each cycle

  • cisplatinDrug

    75 mg/sq m IV over 1 hr Day 1 of each cycle

  • docetaxelDrug

    75 mg/sq m IV over 1 hr Day 1 of each cycle

  • BNP7787Drug

    40 g IV over 30 min Day 1 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ToxicityTime frame: 12 weeks

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • El Camino Hospital

    Mountain View, California

  • Beebe Medical Center

    Lewes, Delaware

  • CCOP - Christiana Care Health Services

    Newark, Delaware

  • St. Francis Hospital

    Wilmington, Delaware

  • St. Joseph Medical Center

    Bloomington, Illinois

  • Graham Hospital

    Canton, Illinois

  • Memorial Hospital

    Carthage, Illinois

  • University of Illinois Cancer Center

    Chicago, Illinois

  • Veterans Affairs Medical Center - Chicago Westside Hospital

    Chicago, Illinois

  • University of Chicago Cancer Research Center

    Chicago, Illinois

  • Louis A. Weiss Memorial Hospital

    Chicago, Illinois

  • Eureka Community Hospital

    Eureka, Illinois

  • Galesburg Clinic

    Galesburg, Illinois

  • Galesburg Cottage Hospital

    Galesburg, Illinois

  • Mason District Hospital

    Havana, Illinois

  • Hopedale Medical Complex

    Hopedale, Illinois

  • Kewanee Hospital

    Kewanee, Illinois

  • McDonough District Hospital

    Macomb, Illinois

  • BroMenn Regional Medical Center

    Normal, Illinois

  • Community Cancer Center

    Normal, Illinois

  • Community Hospital of Ottawa

    Ottawa, Illinois

  • Oncology Hematology Associates of Central Illinois - Ottawa

    Ottawa, Illinois

  • Cancer Treatment Center at Pekin Hospital

    Pekin, Illinois

  • Proctor Hospital

    Peoria, Illinois

  • CCOP - Illinois Oncology Research Association

    Peoria, Illinois

  • Oncology/Hematology Associates of Central Illinois, P.C.

    Peoria, Illinois

  • Methodist Medical Center of Illinois

    Peoria, Illinois

  • OSF St. Francis Medical Center

    Peoria, Illinois

  • Illinois Valley Community Hospital

    Peru, Illinois

  • Perry Memorial Hospital

    Princeton, Illinois

  • St. Margaret's Hospital

    Spring Valley, Illinois

  • Hematology Oncology Associates of the Quad Cities

    Bettendorf, Iowa

  • Holden Comprehensive Cancer Center at University of Iowa

    Iowa City, Iowa

  • Greenebaum Cancer Center at University of Maryland Medical Center

    Baltimore, Maryland

  • Veterans Affairs Medical Center - Baltimore

    Baltimore, Maryland

  • Union Hospital Cancer Center at Union Hospital

    Elkton MD, Maryland

  • Missouri Baptist Cancer Center

    St Louis, Missouri

  • Arch Medical Services, Incorporated at Center for Cancer Care Research

    St Louis, Missouri

  • Cancer Resource Center - Lincoln

    Lincoln, Nebraska

  • Methodist Cancer Center at Methodist Hospital - Omaha

    Omaha, Nebraska

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.